Add Yahoo as a preferred source to see more of our stories on Google. A professional in the event planning division of an international biotechnology trade group is running as a Democrat for the ...

As CDMO giants Wuxi AppTec and WuXi Biologics come under mounting scrutiny for their alleged ties to Chinese government officials, they are losing a key ally in Washington, D.C. Wednesday, the ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Shortly after the arrival of a permanent successor following more than a year under interim CEO Rachel King, the top U.S. biotechnology trade group has bid adieu to its lobbying head. “We can confirm ...

Current Portfolio Allocation for Core Biotech1. Selling my stake in Abcellera Biologics (ABCL) for 18% loss2. Adding to my position in Axsome Therapeutics (AXSM), increasing portfolio weighting from 4 ...

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

Later this month, BIO will hold its annual conference. BIO provides advocacy, business development, and communications services for its members worldwide. BIO came into existence in 1993 through the ...

X4 Pharmaceuticals is rated BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending into 2028. XFOR's primary value lies in its 4WARD Phase 3 trial in ...